Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapyCui Jiang, Tao Sun, Na Li et al.|PeerJ|2019Cited by 18
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trialMin Yan, Fangzhou Xia, Huawu Xiao et al.|EClinicalMedicine|2024Cited by 10